Literature DB >> 15352655

Current status of selenium and other treatments for secondary lymphedema.

Frank Bruns1, Oliver Micke, Michael Bremer.   

Abstract

The unsatisfactory status of lymphedema treatment in patients with cancer warrants an intensified search for new treatment approaches, especially since survival of cancer patients has improved markedly. Lymphedema, regardless of etiology, is essentially incurable, but current therapeutic approaches can reduce swelling, restore shape, and prevent inflammatory episodes. The most conservative approach is physical therapy, including a combination of compression, exercise, and, if possible, massage.Meticulous skin care is needed to avoid recurrent inflammatory episodes. If physical therapy fails, surgery, in the form of reducing or "debulking" operations, is indicated, while microsurgical interventions for certain forms of lymphedema continue to be evaluated. Drug therapy has included the use of diuretics, corticosteroids, and coumarin- or flavonoid-type compounds. Diuretics and corticosteroids may be useful in edema of mixed origin and in palliative circumstances but cannot be recommended for persistent lymphedemas. Coumarin and flavonoids reduce swelling in all types of lymphedema, but their long-term use is problematic. One promising step in drug therapy seems to be the introduction of free-radical scavengers, such as selenium. Present data demonstrate that selenium can enhance the benefits of physical therapy in radiation-induced lymphedemas. The very low toxicity profile of selenium and its cost effectiveness are further arguments for its use in lymphedema treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15352655

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  10 in total

Review 1.  Rare adipose disorders (RADs) masquerading as obesity.

Authors:  Karen L Herbst
Journal:  Acta Pharmacol Sin       Date:  2012-02       Impact factor: 6.150

Review 2.  Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients.

Authors:  G Dennert; M Horneber
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

3.  Change in extracellular fluid and arm volumes as a consequence of a single session of lymphatic massage followed by rest with or without compression.

Authors:  J Maher; K Refshauge; L Ward; R Paterson; S Kilbreath
Journal:  Support Care Cancer       Date:  2012-03-13       Impact factor: 3.603

Review 4.  [Nutrition, lifestyle, physical activity, and supportive care during chemotherapeutic treatment].

Authors:  G Lümmen; T Jäger; F Sommer; T Ebert; B Schmitz-Draeger
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

Review 5.  G protein-coupled receptors as potential drug targets for lymphangiogenesis and lymphatic vascular diseases.

Authors:  William P Dunworth; Kathleen M Caron
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-05       Impact factor: 8.311

6.  [Secondary malignant lymphedema in head and neck tumors].

Authors:  Bernhard Hammerl; Walter Döller
Journal:  Wien Med Wochenschr       Date:  2008

7.  Management of radiation wounds.

Authors:  Subramania Iyer; Deepak Balasubramanian
Journal:  Indian J Plast Surg       Date:  2012-05

8.  Selenium Deficiency in Lymphedema and Lipedema-A Retrospective Cross-Sectional Study from a Specialized Clinic.

Authors:  Christina Pfister; Horst Dawczynski; Franz-Josef Schingale
Journal:  Nutrients       Date:  2020-04-25       Impact factor: 5.717

9.  Sodium Selenite Alleviates Breast Cancer-Related Lymphedema Independent of Antioxidant Defense System.

Authors:  Hye Won Han; Eun Joo Yang; Seung-Min Lee
Journal:  Nutrients       Date:  2019-05-07       Impact factor: 5.717

Review 10.  Emerging Anti-Inflammatory Pharmacotherapy and Cell-Based Therapy for Lymphedema.

Authors:  Ryohei Ogino; Tomoharu Yokooji; Maiko Hayashida; Shota Suda; Sho Yamakawa; Kenji Hayashida
Journal:  Int J Mol Sci       Date:  2022-07-09       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.